Dualitybio Inc.

This study is testing whether a new drug called DB-1303 works better and is as safe as the current treatment, T-DM1, for people with advanced HER2-positive breast cancer that has spread or cannot be removed by surgery. The trial will involve about 224 adults whose cancer has prog…

This large, late-stage trial is comparing a new targeted drug called DB-1303 to standard chemotherapy for people with a specific type of advanced breast cancer. The cancer is hormone-positive and has low levels of a protein called HER2, and it has continued to grow despite hormon…